ReviewRenal failure2025
Protecting kidney function: from mechanisms to therapeutic targets and traditional Chinese medicine.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) has been a significant public health concern globally with its prevalence increasing yearly. Renal fibrosis is the ultimate outcome of CKD progression to end-stage renal disease. However, effective treatment for renal fibrosis is lacking. Therefore, exploring the pathogenesis of renal fibrosis and targeted drugs is of great importance. In this review, we provided an overview of current research advances in the mechanisms of renal fibrosis, summarized the promising therapeutic strategies for delaying CKD progression and proposed possible research priorities in the future. First of all, renal fibrosis is characterized by a complex network composed of various cytokines, inflammatory mediators, and signaling pathways. Employing cutting-edge technologies, such as single-cell RNA sequencing for cell-type-specific fibrosis markers and utilizing big data to develop innovative algorithms, could enhance early diagnostic capabilities and guide stratification. In addition, compared with Western medicine, the diverse active ingredients found in traditional Chinese medicine (TCM) have distinct advantages in modulating the networks of renal fibrosis. Therefore, purifying the effective components of TCM and synthesizing the corresponding compounds might become a hotspot in future research. Adaptive design and using human kidney organoid models for drug screening can determine the active ingredients efficiently. Combination regimens may provide better efficacy by reducing the dosage of a single drug and alleviating the side effects. Moreover, epigenetic reprogramming is expected for the complete treatment of renal fibrosis. Finally, how to address the potential toxicity and off-target effects of pathway inhibitors or TCM compounds still remains a challenge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.